StockData
Kailera Therapeutics, Inc. logo

Kailera Therapeutics, Inc. (KLRA) stock

KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$12.20−0.37 (-2.94%)

Close on Nov 17, 2026Market cap $1.58BP/E –Yield –

Kailera Therapeutics cash

Cash and short-term investments held at the end of each period.

Kailera Therapeutics's cash was $1.04B at Sep 30, 2026. For fiscal 2025 it was $546.06M.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$546.06M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.04B+959.7%
Q2 FY2026Jun 30, 2026$1.17B+1055.9%
Q1 FY2026Mar 31, 2026$581.90M+471.7%
Q4 FY2025Dec 31, 2025$546.06M–
Q3 FY2025Sep 30, 2025$97.91M–
Q2 FY2025Jun 30, 2025$101.37M–
Q1 FY2025Mar 31, 2025$101.78M–

More Kailera Therapeutics figures

See a number that looks wrong?